Group items matching

in title, tags, annotations or url

We are about to enter the year 2018. There will be no better time to start preparing yourself spiritually for the changes and challenges in a new year. Whatever your goals are, I have sessions in all ranges. If you have Unexplainable Store audios in your wishlist, now is the time.

Walgreens Boots Alliance, the American owner of Boots UK, could risk losing billions after a private equity firm interested in buying its UK high street pharmacy chain valued the retailer at a steep discount, The Telegraph reported on Monday (April 11). "Buyout funds CVC and Bain indicated that they were willing to pay just £4bn for the business," the newspaper said, adding that "the consortium bowed out of the running" in March. The US retail giant Walgreens, which acquired Boots in 2014 for £9bn, has put a £7bn price tag on the UK pharmacy retail chain after selling its wholesale arm, Alliance Healthcare, last year. Citing city sources, the newspaper said the low valuation of the pharmacy multiple was "significant" because CVC's UK operations were led by Dominic Murphy, a Walgreens board member involved with Boots for 15 years. "He (Murphy) knows where the bodies are buried," the newspaper quoted one City source as stating. A spokesperson for Boots confirmed that CVC and Bain never lodged a formal offer for the company.

RP Healthcare, a multi-operator, has sold Hammersmith pharmacy in West London to an independent pharmacist for an undisclosed amount. "Mariam Moshref, owner of Fulham Pharmacy, together with her twin brothers, Arya and Jaan Moshref, purchased Hammersmith Pharmacy from Ravi Patel of RP Healthcare," Christie and Co, who handled the sale, said in a statement. This pharmacy operates during standard hours, handling an average of 5,920 items per month, the statement added. Refurbished in 2018, the pharmacy is located on Fulham Palace Road, W6, near Charing Cross Hospital and Hammersmith Underground station. RP Healthcare placed the pharmacy on the market as a strategic move to divest from the area.

Jeremy Meader has resigned as managing director of Numark after five years on the job, and having lead the wider PHOENIX group's sales and marketing teams for about eight years. A press release issued on Wednesday (February 1) said Mr Meader "has decided to leave the business to pursue his career outside of the PHOENIX group", the owner of Numark. It said: "PHOENIX thanks Jeremy for his commitment and dedication over the years and wishes him all the best for his professional and private future." Previous to joining PHOENIX, Mr Meader was head of sales at Alliance Healthcare, a role he took up in 2012 after serving GSK's Consumer Healthcare division for over 13 years in various capacity.

The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June). The paper details how a financially sustainable VPAS can support widened medicines access to patients. VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI). The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues. Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent. "The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme, data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the association.

Specialist business property adviser, Christie & Co, on Tuesday (7 November) announced the sale of Macbon Chemist for the first time in 35 years. The popular community pharmacy, which is located in the heart of the Tollcross area in the east end of Glasgow, dispenses 8,000 National Health System (NHS) items per month. Elizabeth McLaughlin owned the pharmacy since 1987, recently decided to retire and sold the pharmacy for an undisclosed sum. She had been running it along with a team of employed and locum pharmacists. The pharmacy was bought by Ron Badger who owns and runs another pharmacy in the Drumchapel area of Glasgow.

The Manchester Crown Court on Friday (9 December) sentenced three men, Cleave Lewis (35) and brothers, Denis Sutherland (58) and David Sutherland (59), to a total of three years in jail after they pleaded guilty to the illegal sale and supply online of prescription-only medicines and controlled Class B and Class C drugs, worth more than £1.5m. They were found in possession of nearly 1.3m tablets of prescription-only drugs, including powerful sleeping pills, painkillers and anti-anxiety meds, when officers from the Medicines and Healthcare products Regulatory Agency (MHRA) and Greater Manchester Police searched their residential homes and business premises in October 2017. Following investigations by the agency, they also pleaded guilty to illegally making these medicines available online on three different websites for the public to purchase without prescriptions. The officials also recovered controlled medicines, over half a million (525,737) erectile dysfunction, slimming and herbal tablets, with an estimated value of approximately £500k, from them.

A community pharmacy in Consett, County Durham, North East England, has been sold to a locum pharmacist after the previous owner decided to put it on the market following 29 years of ownership. Specialist business property adviser, Christie & Co, recently announced the sale of Moorside Pharmacy, a 30-hour community pharmacy that dispenses an average of 3,200 NHS items per month. Located 1.5 miles west of Consett, the pharmacy shares a building with a small GP surgery in Moorside. Rachel Hurst, who has owned it since 1995, brought it to the market to downsize her operations and focus on her busier pharmacies - one in Consett and two in Crook, County Durham, according to the broker. Following a confidential sales process, locum pharmacist Monju Miah has acquired the pharmacy. He plans to manage it hands-on and introduce additional services that will benefit the local population, the broker stated.

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

Olbas has announced the launch of its new TV ad campaign which will debut across the country this October. The TV campaign, which will be supported by a £1.5 million pound media investment, has been directed by commercial film director, Anthony Farquhar-Smith. The latest Olbas advertising creative will feature a new animated character, Lauren who is suffering with congestion caused by a cold. Lauren will be seen at home as the house begins to fill with balloons causing Lauren to feel uncomfortable and restricted, mimicking the 'bunged up' feeling of a heavy head cold. Olbas then saves the day as we see Lauren reach for a bottle of Olbas Oil to ease the symptoms of congestion, and as a result, the balloons deflate and the house returns to normal. Along with the large media investment, the campaign will also benefit from a strong PR programme to ensure the brand and retail sales are well supported throughout the peak cold and flu season. Owned by family-run health business, Lanes Health, Olbas Oil continues to be manufactured at their Gloucester based factory. Olbas uses only natural essential oils to provide a gentle but effective formulation to ease congestion and enhance breathing passages. The product offer includes Olbas Oil, Olbas For Children, Olbas Inhaler, Olbas Nasal Spray, Olbas Menthol Pastilles and Olbas Bath.

The General Pharmaceutical Council (GPhC) has alerted pharmacists, pharmacy technicians, and pharmacy owners via email regarding new emergency legislation governing the prescribing and supply of puberty-suppressing hormones, commonly known as 'puberty blockers', for children and young people under 18 in England, Wales, and Scotland. The regulations apply to gonadotropin-releasing hormone (GnRH) analogues, used to suppress puberty as part of treating gender incongruence or gender dysphoria in individuals under 18. Effective from 3 June 2024, new private prescriptions for GnRH analogues from prescribers in the European Economic Area (EEA) or Switzerland who are not UK registered are banned from being dispensed in Great Britain for patients under 18. The emergency ban on these medicines will remain in effect until September 3, 2024, the Department of Health and Social Care (DHSC) announced on 29 May, stating that the action has been taken to address risks to "patient safety."

Pharmacy sales specialist, Hutchings Consultants has revealed its market predictions for the next 12 months in a new report. The broker is anticipating that both independent group operators and corporate owners will continue to reassess their existing portfolios in 2024, making strategic disposals of varying sizes. "This is likely to result in transaction volumes remaining high for the foreseeable future," stated the report authored by Paul Steet, Associate Director, Hutchings Consultants. Community Pharmacy Contractual Framework negotiations will be the most notable opportunity for the sector to capitalise upon this year, the broker said, adding that it's "a belated opportunity for the sector to secure a vital uplift to the contract's fixed global sum."

The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years, the British Generic Manufacturers Association has revealed in its new study. The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years. The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028. "This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma." While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of the VPAS Scheme".

The Royal Pharmaceutical Society (RPS) has appointed Neville Carter as its new chief education and membership officer. Neville joins RPS from the Royal Society of Medicine (RSM) where he is currently director of engagement, leading a team of over 60 and responsible for creating a combined directorate accountable for education, membership, philanthropy, and business development. He has, in particular, led on the development of a digital education strategy and launched professional development training programmes for members. Prior to joining the RSM, Neville worked as director of product and sales at the British Medical Association with responsibility for membership growth, supporting corporate transformation and developing and managing member benefits and relationships with third-party providers to support revenue growth. He also has senior manager experience at the RAC and at British Airways. Commenting on the appointment, Paul Bennett, RPS CEO, said: "I'm delighted that Neville will be joining our Executive team. He brings a wealth of relevant experience and this, in combination with a strong existing education and membership team at RPS and a clear ambition to strengthen the relevant functions further, will enable the organisation to deliver a dynamic offering for our members.

Pediatric Wheelchair Strollers are a tried and truth method of transporting children safely and securely, and when the young person in your care has special needs, these devices become indispensable. Fortunately, we carry a great selection of adaptive strollers, specially designed to accommodate a wide range of conditions. pediatric wheelchair for sale Pediatric Wheelchair is a daily necessity for many children. Child wheelchair selection is no different than for an adult. wheelchairs for kids are often an extension of a child's "sense of self" and they should be chosen just as carefully as an adult would chose one for themselves. There are many reasons for needing pediatric wheelchairs, from the recovery of temporary illness or injury to more long term mobility issues. Wheelchairs for kids and very small adults have not been neglected by contemporary wheelchair manufacturers. The special-sized manual child wheelchair is usually equiped with narrow 12" to 14" seats and many offer a number of adjustments to fit the changing physical requirements of a growing child. With options and upgrades, a good pediatric wheelchair will be able to accomodate the needs of a pediatric user for several years. Pros Light Adaptable Growable Will accommodate many seating options CP Chair Cp Chair is Reclining high back, adjustable headrest, solid castor, adjustable seat and adjustable backrest, with 5 pieces seat belt. Suitable for baby under three years old. It is the new product of our production line in CP wheel chair which is the exclusive wheelchair . Applications: Use for baby cerebral paralysis Well fitted to user. Many options. Many accessories. Very adjustable. Excellent positioning ability. Features Ultra light weight aluminum alloy frame Epoxy powder coated frame Detachable arm rest provided Height adjustable and detachable head rest Hydraulic reclining high back for a comfortable posture Detachable back and seat pad Extra cush

Independent pharmacy chain, Peak Pharmacy, has sold two of its smaller branches - one in Little Eaton, Derbyshire, and the other in Burton-on-Trent, Staffordshire. Founded in 1981 by Peter and Jane Cattee, Peak Pharmacy has over 150 pharmacies across the UK. The pair of Midlands pharmacies dispense an average of circa 2,800 items per month, according to specialist business property adviser, Christie & Co, which announced the sale. The pharmacy in Burton-on-Trent has been acquired by a local first-time buyer, Mohammed Wasim Gul, while the pharmacy in Little Eaton has been purchased by Amul Telrandhe, who is also the owner of Derwent Pharmacy in Derby.

Types of CP Associated With Muscle Tone Cerebral palsy comes in several types, which may be associated with muscle tone or specific body parts. Those associated with muscle tone include: spastic CP, where abnormally high muscle tone causes problems with movement, usually in the legs and hips; ataxia, which is marked by involuntary muscle movements; athetoid, which prevents sufferers from maintaining a fixed muscle position (for example, grasping and holding); and mixed, where symptoms of both spastic and athetoid CP occur. Cerebral Palsy: Hope Through Research: Detailed information from the National Institute of Neurological Disorders and Stroke, including facts on the causes, risk factors, warning signs, and types of CP. Definitions and Accommodations for Cerebral Palsy: Information on the types of CP and how to accommodate and interact with severe sufferers. From Kentucky's Office for the Americans With Disabilities Act. United Cerebral Palsy Association: Nonprofit organization that offers a nationwide network of affiliates aimed at expanding the rights, freedoms, and opportunities of those with cerebral palsy. Health Encyclopedia: Cerebral Palsy: Facts on the types, causes, prevalence, and accommodations related to cerebral palsy. Provided by the Florida Agency for Health Care Administration. Cost of Cerebral Palsy: Information on the human and economic impact of cerebral palsy, presented in the form of an academic report composed by the Environmental Protection Agency. Types of CP Associated With Body Parts Certain types of cerebral palsy are associated with specific body parts rather than with the general condition of the muscular system. These types include: quadriplegia, in which all four limbs suffer severe motor dysfunction and a general inability to work together; hemiplegia, in which the limbs on one side of the body are severely affected, with the impact more pronounced in the digits; and diplegia, which causes problems with mus

STADA has appointment Nigel Stephenson as General Manager UK with effect from 1 August 2023. Based in Huddersfield, UK, Stephenson will report directly to STADA's Head of Western Europe and Germany, Stephan Eder. He will take over from Rudolf Bär, who has successfully led the UK business for almost one year in addition to his responsibilities for STADA's Mid-Sized European Markets.| A dynamic and modern commercial leader with extensive experience in sales and marketing across Western, Central and Eastern Europe, and the UK in leading pharmaceutical, consumer healthcare and fast-moving consumer goods companies. He joins STADA from consumer healthcare leader Haleon, where he most recently served as General Manager Switzerland. "With his strong people and results orientation, along with deep purpose-driven engagement, Nigel will support our UK team in realizing its full potential through innovative and inclusive leadership," stated Eder.

Pharmaceutical companies AbbVie and Eli Lilly have withdrawn from Britain's voluntary medicines pricing agreement, an industry body said on Monday. Companies are increasingly arguing that it is no longer possible to justify the UK's "voluntary scheme" to global boardrooms and investors as repayment rates in 2023 have surged to 26.5 per cent of revenue, the Association of the British Pharmaceutical Industry (ABPI) said in a statement. "The current scheme has harmed innovation, with costs spiralling out of control, and the UK falling behind other major countries to be left as a global outlier," said Laura Steele, president and general manager for Eli Lilly's Northern Europe division. ABPI said it was seeking early talks with the government to set out a new future settlement. In December, the industry body had said the government raised the amount manufacturers of branded medicines within the voluntary scheme will be required to return to almost £3.3 billion in sales revenue from an earlier amount of £1.8 billion.

Novartis on Wednesday (February 1) predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4 per cent to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya. Novartis said it was on track to spin off its generics unit Sandoz in the second half of the year as part of its effort to sharpen its focus on its patented prescription medicines. Analysts have welcomed a programme unveiled in 2022 to trim costs and cut 8,000 jobs and plans to focus on fewer therapy areas and drug technologies. But the market has been underwhelmed by prospects for medium-term growth from new drugs.